Swedish Orphan Biovitrum Management
Management criteria checks 3/4
Swedish Orphan Biovitrum's CEO is Guido Oelkers, appointed in May 2017, has a tenure of 7.5 years. total yearly compensation is SEK48.88M, comprised of 25.1% salary and 74.9% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth SEK127.36M. The average tenure of the management team and the board of directors is 5.8 years and 4 years respectively.
Key information
Guido Oelkers
Chief executive officer
SEK 48.9m
Total compensation
| CEO salary percentage | 25.1% |
| CEO tenure | 7.5yrs |
| CEO ownership | 0.1% |
| Management average tenure | 5.8yrs |
| Board average tenure | 4yrs |
Recent management updates
Recent updates
Swedish Orphan Biovitrum AB (publ) Just Beat EPS By 95%: Here's What Analysts Think Will Happen Next
Oct 27
Earnings Beat: Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Jul 19Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly
Jun 24Here's Why Shareholders May Consider Paying Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) CEO A Little More
May 08Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Apr 27Investors Still Waiting For A Pull Back In Swedish Orphan Biovitrum AB (publ) (STO:SOBI)
Apr 24Swedish Orphan Biovitrum AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Apr 06Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly
Mar 05Swedish Orphan Biovitrum's (STO:SOBI) Weak Earnings May Only Reveal A Part Of The Whole Picture
Feb 15Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Earnings Haven't Escaped The Attention Of Investors
Jan 17Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?
Nov 24Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?
Jul 07Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?
Apr 02Is Swedish Orphan Biovitrum AB (publ) (STO:SOBI) Trading At A 30% Discount?
Jan 11These 4 Measures Indicate That Swedish Orphan Biovitrum (STO:SOBI) Is Using Debt Reasonably Well
Dec 27Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?
Sep 28Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?
Jun 26CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | SEK 4b |
| Jun 30 2024 | n/a | n/a | SEK 2b |
| Mar 31 2024 | n/a | n/a | SEK 2b |
| Dec 31 2023 | SEK 49m | SEK 12m | SEK 2b |
| Sep 30 2023 | n/a | n/a | SEK 3b |
| Jun 30 2023 | n/a | n/a | SEK 3b |
| Mar 31 2023 | n/a | n/a | SEK 3b |
| Dec 31 2022 | SEK 47m | SEK 11m | SEK 3b |
| Sep 30 2022 | n/a | n/a | SEK 2b |
| Jun 30 2022 | n/a | n/a | SEK 3b |
| Mar 31 2022 | n/a | n/a | SEK 3b |
| Dec 31 2021 | SEK 42m | SEK 10m | SEK 3b |
| Sep 30 2021 | n/a | n/a | SEK 3b |
| Jun 30 2021 | n/a | n/a | SEK 3b |
| Mar 31 2021 | n/a | n/a | SEK 3b |
| Dec 31 2020 | SEK 33m | SEK 10m | SEK 3b |
| Sep 30 2020 | n/a | n/a | SEK 3b |
| Jun 30 2020 | n/a | n/a | SEK 3b |
| Mar 31 2020 | n/a | n/a | SEK 4b |
| Dec 31 2019 | SEK 33m | SEK 10m | SEK 3b |
| Sep 30 2019 | n/a | n/a | SEK 3b |
| Jun 30 2019 | n/a | n/a | SEK 3b |
| Mar 31 2019 | n/a | n/a | SEK 3b |
| Dec 31 2018 | SEK 26m | SEK 9m | SEK 2b |
| Sep 30 2018 | n/a | n/a | SEK 2b |
| Jun 30 2018 | n/a | n/a | SEK 2b |
| Mar 31 2018 | n/a | n/a | SEK 1b |
| Dec 31 2017 | SEK 16m | SEK 5m | SEK 1b |
Compensation vs Market: Guido's total compensation ($USD4.45M) is above average for companies of similar size in the Swedish market ($USD2.21M).
Compensation vs Earnings: Guido's compensation has been consistent with company performance over the past year.
CEO
Guido Oelkers (59 yo)
7.5yrs
Tenure
SEK 48,883,000
Compensation
Dr. Guido Oelkers is a Director of Dova Pharmaceuticals Inc. since November 12, 2019. Dr. Oelkers has been the Chief Executive Officer and President at Swedish Orphan Biovitrum AB since May 22, 2017. He se...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & President | 7.5yrs | SEK 48.88m | 0.12% SEK 127.4m | |
| Chief Financial Officer | 6.3yrs | no data | 0.016% SEK 16.8m | |
| General Counsel & Head of Legal Affairs | 5.8yrs | no data | 0.0089% SEK 9.1m | |
| Head of Strategy & Corporate Development | 2.8yrs | no data | 0.0029% SEK 2.9m | |
| Head of Human Resources | 1.8yrs | no data | no data | |
| Senior Scientific & Medical Advisor | 7.8yrs | no data | 0.0047% SEK 4.8m | |
| Head of International | 7.1yrs | no data | 0.012% SEK 11.8m | |
| Head of Europe | 5.8yrs | no data | 0.0077% SEK 7.9m | |
| Head of North America | 3.8yrs | no data | no data | |
| Head of Strategic Transformation Operations | no data | no data | 0.0018% SEK 1.9m | |
| Head of Technical Operations | 2.7yrs | no data | 0.0032% SEK 3.3m | |
| Senior VP | 1.8yrs | no data | no data |
5.8yrs
Average Tenure
56.5yo
Average Age
Experienced Management: SOBI's management team is seasoned and experienced (5.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of Scientific Advisory Board | 23.8yrs | SEK 158.00k | no data | |
| Director | 13.6yrs | SEK 828.00k | 0.0067% SEK 6.8m | |
| Director | 1.5yrs | SEK 463.00k | 0.0010% SEK 1.0m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Chairman | 10.5yrs | SEK 770.00k | 0.00099% SEK 1.0m | |
| Independent Director | 4.5yrs | SEK 827.00k | 0.0021% SEK 2.1m | |
| Director | 3.5yrs | SEK 673.00k | 0.00017% SEK 174.1k | |
| Employee Representative Director | 1.8yrs | no data | 0.0013% SEK 1.3m | |
| Independent Director | 1.5yrs | SEK 433.00k | no data |
4.0yrs
Average Tenure
54.5yo
Average Age
Experienced Board: SOBI's board of directors are considered experienced (4 years average tenure).